These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 18832247)

  • 21. Hepatitis B virus genotypes: an overview.
    Mahtab MA; Rahman S; Khan M; Karim F
    Hepatobiliary Pancreat Dis Int; 2008 Oct; 7(5):457-64. PubMed ID: 18842489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of chronic hepatitis B: new goals and new treatments.
    Mauss S
    Minerva Med; 2009 Dec; 100(6):447-58. PubMed ID: 20010480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathobiology of HBV mutants and clinical impact for treatment monitoring.
    Si Ahmed SN; Zoulim F
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):309-20. PubMed ID: 19344244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B therapies and antiviral resistance detection and management.
    Holness G; Carriero DC; Dieterich DT
    Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):693-9. PubMed ID: 19929588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Common hepatitis B drug linked to HIV antiviral resistance.
    Future Microbiol; 2007 Apr; 2(2):104. PubMed ID: 17687802
    [No Abstract]   [Full Text] [Related]  

  • 27. Role of viral replication in extrahepatic syndromes related to hepatitis B virus infection.
    Mason A
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):53-66. PubMed ID: 16554707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human immunodeficiency virus and hepatitis B and C coinfection: pathogenic interactions, natural history, and therapy.
    Kim AY; Chung RT; Polsky B
    AIDS Clin Rev; 2000-2001; ():263-306. PubMed ID: 10999223
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
    Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
    Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tenofovir helps beat hepatitis B.
    TreatmentUpdate; 2003 Jan; 15(1):4. PubMed ID: 12630369
    [No Abstract]   [Full Text] [Related]  

  • 32. Molecular virology and the development of resistant mutants: implications for therapy.
    Locarnini S
    Semin Liver Dis; 2005; 25 Suppl 1():9-19. PubMed ID: 16103977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B virus infection--natural history and clinical consequences.
    Ganem D; Prince AM
    N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment modalities for hepatitis B viral infection and resistance to antiviral therapy.
    Pai SB; Pai RB; Schinazi RF
    Panminerva Med; 2003 Sep; 45(3):165-73. PubMed ID: 14618114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing clinical development programs for anti-hepatitis B virus drugs.
    Brown NA
    Methods Mol Med; 2004; 96():499-537. PubMed ID: 14762289
    [No Abstract]   [Full Text] [Related]  

  • 36. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
    Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
    J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-hepatitis B virus coinfection: questions and answers.
    Valenti WM
    AIDS Read; 2005 May; 15(5):226-30. PubMed ID: 15900632
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
    Filippini P; Coppola N; Pisapia R; Scolastico C; Marrocco C; Zaccariello A; Nacca C; Sagnelli C; De Stefano G; Ferraro T; De Stefano C; Sagnelli E
    AIDS; 2006 Jun; 20(9):1253-60. PubMed ID: 16816553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons from HIV and hepatitis viruses.
    Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
    Antiviral Res; 2004 Aug; 63 Suppl 1():S11-8. PubMed ID: 15450381
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
    Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
    J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.